EU Produces Guide On 'Challenges' To NASH Drug Development
Executive Summary
Regulatory experience with the development of new medicines for non-alcoholic steatohepatitis is limited, and because of the high unmet need, a conditional marketing authorization approach should be considered, the European Medicines Agency says.